Overview Request Sample Pages Request Customization Download PDF
You are viewing: Italy Chemiluminescence Immunoassay Market analysis

The Italy Chemiluminescence Immunoassay Market was valued at $283.9 Million in 2026 and projected to reach to $389.6 Million by 2031, representing a compound annual growth rate of CAGR 6.5%. Italy's chemiluminescence immunoassay market is poised for steady growth through 2031, supported by the country's advanced healthcare infrastructure and increasing demand for accurate diagnostic solutions.

Italy Chemiluminescence Immunoassay Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Italy Chemiluminescence Immunoassay Market Trends and Insights

  • Italy's healthcare sector is increasingly adopting advanced diagnostic technologies, with chemiluminescence immunoassay systems becoming integral to clinical laboratories and hospital settings across the country.
  • The growth trajectory reflects Italy's commitment to modernizing its diagnostic infrastructure and improving patient outcomes through precision medicine. The Italian market benefits from strong healthcare spending, an aging population requiring frequent diagnostic testing, and rising prevalence of chronic diseases.
  • Italy's established pharmaceutical and diagnostics industry supports the adoption of chemiluminescence immunoassay platforms in both public and private healthcare facilities.
  • Between 2026 and 2031, Italy is expected to see sustained demand driven by technological advancements, regulatory support for in vitro diagnostics, and increased automation in clinical laboratories throughout the country..

Key Market Statistics

  • CAGR (2026-2031) CAGR 6.5%
  • Market Size, 2026 ~USD 283.9 Million
  • Forecast, 2031 ~USD 389.6 Million
  • Country Italy

Italy Chemiluminescence Immunoassay Market Overview

Market Valuation Growth :

Italy's chemiluminescence immunoassay market is valued at USD 283.9 million in 2026 and is projected to reach USD 389.6 million by 2031, demonstrating robust expansion in the Italian diagnostic sector.

Steady CAGR Performance :

The Italian market is growing at a CAGR of 6.5% from 2026 to 2031, slightly below the global average of 7.2%, reflecting a mature but consistently expanding healthcare diagnostics landscape.

Healthcare Infrastructure Modernization :

Italian clinical laboratories and hospital settings are increasingly adopting advanced chemiluminescence immunoassay systems, driven by investments in modernizing diagnostic capabilities across public and private healthcare facilities.

Regional Healthcare Standards :

Italy's strong healthcare system and regulatory framework support the integration of high-precision immunoassay technologies, positioning the country as a significant market within Southern Europe.

Italy Chemiluminescence Immunoassay Market Dynamics

  • The Italian healthcare system's emphasis on precision medicine and early disease detection is driving adoption of chemiluminescence immunoassay systems in both hospital laboratories and specialized diagnostic centers.
  • Investment in healthcare modernization and the aging population's healthcare needs will continue to fuel market expansion.
  • However, growth remains measured compared to global trends, reflecting market maturity and competitive pricing pressures in the Italian healthcare sector..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • CONMED Corporation

    Key Takeaways

    • Italy's chemiluminescence immunoassay market is valued at USD 283.9 million in 2026 and will grow to USD 389.6 million by 2031.
    • Italy's market is expanding at a 6.5% CAGR, driven by aging demographics and increased diagnostic testing demand.
    • Italy's healthcare infrastructure modernization and strong regulatory framework support adoption of advanced immunoassay technologies.
    • Italy's clinical laboratories are increasingly automating diagnostic workflows, boosting chemiluminescence immunoassay system deployment.

    Chemiluminescence Immunoassay Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment ONCOLOGY (Application)
    Forecast Period 2026–2031
    Growth Rate CAGR of 7.2% from 2026 to 2031
    Largest Segment CONSUMABLES (Product Type)
    Market Size Base Year (Billions) ~USD 11.58 (2026)
    Revenue Forecast (Billions) ~USD 16.39 (2031)
    Segments Covered Product Type, Technology, Sample Type, Application, End User

    Italy Chemiluminescence Immunoassay Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product Type

    • Consumables
    • Instruments

    By Technology

    • Chemiluminescence Enzyme Immunoassays (Cleia)
    • Electrochemiluminescence Immunoassays (Ecli)
    • Microparticle Chemiluminescence Immunoassays

    By Sample Type

    • Blood
    • Other Sample Types
    • Saliva
    • Urine

    By Application

    • Allergy Diagnostics
    • Autoimmune Disorders
    • Blood Screening
    • Bone & Mineral Disorders
    • Cardiology
    • Endocrinology
    • Gastroenterology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Newborn Screening
    • Oncology
    • Other Applications
    • Respiratory Diseases
    • Therapeutic Drug Monitoring
    • Toxicology

    By End User

    • Clinical Laboratories
    • Hospitals
    • Other End Users
    • Pharmaceutical & Biotechnology Companies And Cros

    ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    CLINICAL LABORATORIES97.6102.4107.8113.8120.4127.8135.9144.96.1
    HOSPITALS153.7161.8170.9181.1192.2204.7218.5233.86.5
    OTHER END USERS25.526.627.829.130.632.234365.3
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS32.233.735.437.239.341.54446.85.8
    TOTAL309324.4341.9361.2382.5406.2432.4461.46.2

    Target Audience

    • Diagnostic Equipment Manufacturers : Companies manufacturing chemiluminescence immunoassay systems need Italy-specific market data to assess market size, growth potential, and competitive positioning for product launches and expansion strategies.
    • Healthcare Facility Operators : Hospital administrators and laboratory directors in Italy require market insights to justify capital investments in diagnostic equipment and understand technology adoption trends within their region.
    • Medical Device Distributors : Italian and European distributors need country-level market intelligence to evaluate sales potential, identify growth segments, and optimize inventory and sales strategies for immunoassay products.
    • Healthcare Investors & PE Firms : Investment professionals targeting Italy's healthcare sector need detailed market forecasts and growth metrics to identify acquisition targets and evaluate investment opportunities in diagnostic companies.
    • Healthcare Consultants & Analysts : Consulting firms and research analysts advising Italian healthcare organizations require granular market data to support strategic recommendations and competitive benchmarking analyses.

    Key Companies in the Italy Chemiluminescence Immunoassay Market

    CompanyHQOwnershipStrongest segments
    ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
    SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and bioproduction solutions),Life Sciences (instruments, genomics, and research tools),Diagnostics (clinical instruments and consumables),
    DIASORIN S.P.A.ItalyPublic CompanyLIAISON XL / LIAISON XS immunodiagnostics,Molecular diagnostics (Simplexa, congenital CMV, LIAISON PLEX assays),xMAP technology platform and related IVD solutions,
    QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Point of Care,Transfusion Medicine,
    SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers & reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems & reagents,Blood gas / electrolyte / urinalysis,
    SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.ChinaPublic CompanyImmunoassay analyzers and reagents,Biochemistry/Electrolyte systems and reagents,Integrated systems and lab automation,
    TOSOH CORPORATIONJapanPublic CompanyBasic chemicals and chlor-alkali (caustic soda, sodium bicarbonate, related),Vinyls, PVC chain, and petrochemicals (VCM, ethylene, propylene, aromatics),Advanced materials (battery materials, quartzware, silica glass, thin films, zeolites, zirconia, beads),
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Consumables,Informatics and Software,
    SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.ChinaPublic CompanyPatient monitoring & life support (incl. ventilators, anesthesia, defibrillation, infusion),Ultrasound & medical imaging (incl. radiology, emergency ultrasound, endoscope camera systems),In-vitro diagnostics (CLIA, chemistry, hematology),

    ABBOTT

    Abbott is a United States-based public company founded in 1888 with 115,000 employees, operating in the healthcare and pharmaceutical sectors.

    SIEMENS HEALTHINEERS AG

    Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and diagnostics.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating across diversified industrial and life sciences sectors.

    DIASORIN S.P.A.

    DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees engaged in in vitro diagnostics and molecular diagnostics.

    QUIDELORTHO CORPORATION

    QuidelOrtho Corporation is a United States-based public company founded in 1979 with 6,500 employees specializing in diagnostic solutions.

    SYSMEX CORPORATION

    Sysmex Corporation is a Japanese public company founded in 1968 with 10,861 employees focused on in vitro diagnostics and hematology systems.

    SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.

    Shenzhen New Industries Biomedical Engineering Co., Ltd. is a Chinese public company founded in 1995 with 2,785 employees operating in the biomedical diagnostics sector.

    TOSOH CORPORATION

    Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees engaged in specialty chemicals and diagnostics.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees providing life science research and clinical diagnostics products.

    SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

    Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a Chinese public company founded in 1991 with 21,288 employees manufacturing medical devices and diagnostics equipment.

    Reasons to Buy this Report

    • Italy-Specific Market Sizing : Obtain precise valuation data for Italy's chemiluminescence immunoassay market with detailed 2026-2031 forecasts, enabling accurate business planning and investment decisions tailored to the Italian healthcare landscape.
    • Competitive Landscape Intelligence : Understand market dynamics specific to Italy, including local competitor positioning, regulatory requirements, and healthcare procurement patterns that differ from broader European markets.
    • Growth Opportunity Identification : Identify high-potential segments within Italy's diagnostic sector, including hospital networks, private laboratories, and emerging diagnostic centers driving the 6.5% CAGR expansion.
    • Strategic Market Entry Planning : Develop targeted go-to-market strategies for Italy with insights into healthcare infrastructure, reimbursement policies, and adoption rates specific to Italian clinical settings.
    • Investment Risk Assessment : Evaluate market maturity, growth sustainability, and competitive intensity in Italy to make informed investment and partnership decisions in the Italian diagnostic equipment sector.

    Frequently asked questions

    What is the current market size of chemiluminescence immunoassay in Italy?

    Italy's chemiluminescence immunoassay market is valued at USD 283.9 million in 2026.

    What is the projected market size for Italy by 2031?

    Italy's chemiluminescence immunoassay market is projected to reach USD 389.6 million by 2031.

    What is the CAGR for Italy's chemiluminescence immunoassay market?

    Italy's market is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2031.

    What factors are driving growth in Italy's chemiluminescence immunoassay market?

    Growth in Italy is driven by an aging population, increased prevalence of chronic diseases, healthcare infrastructure modernization, and rising automation in clinical laboratories.

    Which healthcare settings in Italy are adopting chemiluminescence immunoassay systems?

    Italy's public and private hospitals, clinical laboratories, and diagnostic centers are increasingly adopting chemiluminescence immunoassay platforms for improved diagnostic accuracy and efficiency.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the CLIA market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and companies' SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the CLIA market. It was also used to obtain important information on key players, market classification, and segmentation aligned with industry trends to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after secondary research provided information on the CLIA market. Several primary interviews were conducted with market experts from both the demand and supply sides across major countries of North America, Europe, Asia Pacific,  Latin America, and the Middle East & Africa. Primary data was collected through questionnaires, emails, and telephonic interviews. The primary sources from the supply side included various industry experts, such as Chief Executive Officers (CXOs), Vice Presidents (VPs), Directors from business development, marketing, and product development/innovation teams, as well as related key executives from manufacturers and distributors operating in the CLIA market.; and key opinion leaders.

    Primary interviews were conducted to gather insights into market statistics, revenue from products and services, market breakdowns, market size estimates, market forecasting, and data triangulation. Primary research also helped in understanding the various trends in technology, applications, verticals, and regions. Stakeholders from the demand side, customers/end users who are using infection control products, were interviewed to understand the buyer’s perspective on the suppliers, products, and their current usage and the future outlook of their business, which will affect the overall market.

    The following is a breakdown of the primary respondents:

    Chemiluminescence Immunoassay Market Size, and Share

    Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
    Note 2: Other primaries include sales managers, marketing managers, and product managers.
    Note 3: Companies are classified into tiers based on their total revenue.
    As of 2023: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, Tier 3=<USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The research methodology used to estimate the size of the CLIA market includes the following details.

    The market sizing was conducted on a global basis.

    Country-level Analysis: The size of the CLIA market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products in the overall CLIA market was obtained from secondary data and validated by primary participants to arrive at the total CLIA market. Primary participants further validated the numbers.

    Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

    Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
    Approach 2: Geographic adoption trends for individual product segments by end user and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

    At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall CLIA market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

    Global Chemiluminescence Immunoassay Market : Top-Down and Bottom-Up Approach

    Chemiluminescence Immunoassay Market Top Down and Bottom Up Approach

    Data Triangulation

    The market was split into several segments and subsegments after determining the overall market size, using the market sizing processes. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for each market segment and subsegment. The data was triangulated by examining various factors and trends on both the demand and supply sides of the CLIA market.

    Market Definition

    Chemiluminescent immunoassay (CLIA) is an immunoassay technique in which the label, i.e., the indicator of the analytical reaction, is a luminescent molecule. CLIA is a variation of the standard enzyme immunoassay (EIA), a biochemical technique used in immunology. This variation technique can be used for medical diagnosis and in several other industries for various applications. In recent years, CLIA has attracted increasing attention across fields such as clinical diagnosis, life sciences, food safety, environmental monitoring, and pharmaceutical analysis, due to its high specificity, high sensitivity, broad applicability, simple instrumentation, and wide linear range.

    Key Stakeholders

    • CLIA manufacturers and distributors
    • CLIA analyzers & consumables manufacturers
    • Healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and governing bodies)
    • Healthcare institutions (hospitals and outpatient clinics)
    • Distributors and suppliers
    • Research institutes
    • Health insurance payers
    • World Health Organization (WHO)
    • Organisation for Economic Co-operation and Development (OECD)
    • National Institutes of Health (NIH)
    • Centers for Disease Control and Prevention (CDC)
    • Annual Reports/SEC Filings, Investor Presentations, and Press Releases of Key Players
    • White Papers, Journals/Magazines, and News Articles
    • Paid Databases, such as Factiva, D&B Hoovers, and Bloomberg Business

    Report Objectives

    • To define, describe, segment, and forecast the global CLIA market by product type, technology, sample type, application, end user, and region.
    • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall CLIA market.
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
    • To forecast the size of the CLIA market in five main regions, along with their respective key countries, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile key players in the global CLIA market and comprehensively analyze their core competencies and market shares.
    • To track and analyze competitive developments such as acquisitions, expansions, partnerships, agreements, and collaborations; and product launches and approvals.
    • To benchmark players within the CLIA market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

    Available customizations:

    Based on the given market data, MarketsandMarkets offers customizations tailored to the company’s specific needs. The following customization options are available for the report:

    Geographic Analysis

    • Further breakdown of the Rest of Asia Pacific CLIA market into Thailand, Indonesia, Philippines, Vietnam, Hong Kong, and other countries
    • Further breakdown of the Rest of Europe CLIA market into Belgium, Russia, the Netherlands, Switzerland, and other countries.
    • Further breakdown of the Rest of Latin America CLIA market into Argentina, Peru, and other countries.

     

    Get the Full Chemiluminescence Immunoassay Market Report

    Full forecast, segment splits, and company analysis for all Chemiluminescence Immunoassay Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status